A revolutionary technique that promises to restore the sight of millions has been carried out for the first time worldwide in a British hospital.
Taking as little as 45 minutes, the procedure offers hope to those with age-related macular degeneration, the leading cause of blindness in adults globally.
It affects more than 600,000 adults in the UK, blighting the lives of a quarter of the over-60s.
In the breakthrough developed at University College London, doctors inserted a patch of stem cells into the retina of a woman who has lost her central vision.
They hope the procedure, carried out at Moorfields Eye Hospital in the capital, will restore the 60-year-old’s sight but will not know the outcome until December.
However, doctors said she suffered no complications and her eye is recovering well from the procedure.
This first operation has begun a clinical trial involving ten patients. If successful, the technique could be available on the NHS within two-and-a-half years.
The procedure, which has attracted the support of medical giant Pfizer, is carried out under local anaesthetic. It involves taking a single embryonic stem cell and growing it into a 6mm patch of 100,000 retinal pigment cells.
That patch is then rolled into a thin tube, which is injected through a tiny slit in the eye.
Once unfurled, it is placed behind the retina where scientists hope it will replace the faulty cells.
The operation is a milestone in the London Project to Cure Blindness established ten years ago with the aim of curing vision loss in patients with age-related macular degeneration.
The first step has been carried out on the wet form of the condition when a patient bleeds at the back of the eye. But scientists are confident it could also be used for the more common dry AMD, which affects 85 per cent of British sufferers.
The Latest on: Age-related macular degeneration
via Google News
The Latest on: Age-related macular degeneration
- Innovent Announces First Patient Dosed in a Phase I Clinical Trial of IBI302 for the Treatment of Wet AMD on April 17, 2019 at 5:08 pm
"Age-related macular degeneration (AMD) is one of the leading causes of irreversible vision impairment among China's elderly population. Although the efficacy of current therapies for wet AMD is ... […]
- Adverum Announces Clinical Hold, But It Should Not Hinder Its Gene Therapy Path on April 17, 2019 at 7:53 am
Adverum announced that the FDA has placed a clinical hold on one of its gene therapy products known as ADVM-022 to treat patients with wet age-related macular degeneration. Responses for the FDA's ... […]
- A hidden footprint: embryological origins of age related macular degeneration on April 17, 2019 at 6:27 am
To address this, Sivapathasuntharam et al.  examined retinal development in Cfh−/− and Cfh+/− mice and showed significant disruptions at the retinal/RPE interface. However, after retinal ... […]
- FDA accepts Novartis’s BLA for brolucizumab for treatment of wet AMD on April 17, 2019 at 12:07 am
Novartis said that the US Food and Drug Administration (FDA) has accepted its biologics license application (BLA) for brolucizumab (RTH258) as a potential treatment for wet age-related macular ... […]
- Novartis' BLA Acceptance Allows Entrance Into Large And Turbulent Wet AMD Market on April 16, 2019 at 8:24 pm
Novartis announced that the FDA had accepted its BLA for brolucizumab to treat patients with wet age-related macular degeneration. The company chose to use one of its priority review vouchers to ... […]
- FDA places clinical hold on IND application for Adverum’s wet AMD gene therapy on April 16, 2019 at 8:21 am
The FDA has placed a clinical hold on Adverum Biotechnologies’ investigational new drug application for its gene therapy candidate for wet age-related macular degeneration until it receives further ... […]
- Novartis' speedy brolucizumab review tees up battle with Eylea, Lucentis on April 16, 2019 at 7:28 am
Look out, Roche and Regeneron—Novartis eye candidate brolucizumab is on its way. Monday, the FDA said it had granted the wet age-related macular degeneration (AMD) prospect its priority review status, ... […]
- Artificial intelligence project identifies existing drugs that have potential to treat AMD on April 16, 2019 at 6:59 am
The initial results from an artificial intelligence project show a number of existing drugs have the potential to reduce sight loss from age-related macular degeneration, the leading cause of sight ... […]
- Treatment for Wet Age-Related Macular Degeneration Receives Biologics License Application Approval on April 16, 2019 at 6:54 am
Officials with the FDA have accepted Novartis’ Biologics License Application (BLA) for brolucizumab (RTH258), a humanized single-chain antibody fragment (scFv), for the treatment of wet age-related ... […]
- LumiThera Announces First Patient Enrollment in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration on April 11, 2019 at 4:49 am
"I am delighted that we are able to offer some of our patients this very exciting new treatment," remarked Professor Ben Burton, Visiting Professor at the University of East Anglia, and ... […]
via Bing News